Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS5679374 A
Type de publicationOctroi
Numéro de demandeUS 08/367,422
Date de publication21 oct. 1997
Date de dépôt30 déc. 1994
Date de priorité30 déc. 1993
État de paiement des fraisPayé
Autre référence de publicationCA2138873A1, CA2138873C, DE69400428D1, DE69400428T2, EP0661036A1, EP0661036B1
Numéro de publication08367422, 367422, US 5679374 A, US 5679374A, US-A-5679374, US5679374 A, US5679374A
InventeursChantal Fanchon, Alain Ribier, Evelyne Segot, Jean-Thierry Simonnet
Cessionnaire d'origineL'oreal
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Anti-acne composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
US 5679374 A
Résumé
Compositions which comprise a first dispersion of lipid vesicles which are capable of penetrating into the deep layers of the skin and which contain at least one active agent chosen from antimicrobial agents, antiseptic agents, antibiotics, anti-inflammatory agents, anti-seborrhoeic agents, retinol and the derivatives thereof, for treating these deep layers, and a second dispersion of lipid vesicles which are capable of penetrating into the surface layers of the skin and which contain at least one active agent chosen from keratolytic agents, protective agents, moisturizing agents and antioxidants, for treating these surface layers, are particularly effective for the treatment of acne.
Images(7)
Previous page
Next page
Revendications(15)
What is claimed as new and desired to be secured by Letters Patent of the Unit States is:
1. An anti-ache composition for the simultaneous treatment of the layers of the stratum corneum and deep layers of the skin comprising a dispersion mixture of:
(a) a first dispersion of lipid vesicles which are capable of penetrating into the deep layers of the skin and containing at least one active agent selected from the group consisting of antimicrobial agents, anti-inflammatory agents, anti-seborrhoeic agents, retinol and retinol compounds, for treating these deep layers; and
(b) a second dispersion of lipid vesicles which are capable of penetrating into the layers of the stratum corneum of the skin and which contain at least one active agent selected from the group consisting of keratolytic agents, protective agents, moisturizing agents and anti-oxidants, for treating these layers of the stratum corneum,
and wherein said vesicles of said first dispersion ensure a distribution of N-(1-oxyl-2,2,6,6-tetramethyl-4-piperidyl)-N-dimethyl-N-hydroxyethylammonium iodide (ASL) in the stratum corneum>1 that said vesicles of said second dispersion ensure a distribution of ASL in the stratum corneum<1
2. The composition of claim 1, wherein said vesicles of said first dispersion are in a fluid state at room temperature and said vesicles of said second dispersion are in a gelled state at room temperature.
3. The composition of claim 1, wherein said vesicles of said first dispersion exhibit an encapsulation potential of glucose for at least 24 hours, and said vesicles of said second dispersion exhibit an encapsulation potential of glucose for less than 24 hours.
4. The composition of claim 1, wherein said vesicles of said first dispersion are formed of lipids having at least one linear and saturated fatty chain having from 16 to 30 carbon atoms.
5. The composition of claim 1, wherein said vesicles of said first dispersion are formed of at .least one lipid selected from the group consisting of natural hydrogenated phospholipids, saturated synthetic phospholipids, polyol alkyl ethers having at least one linear fatty chain, polyol alkyl esters having at least one fatty chain, and mixtures thereof.
6. The composition of claim 1, wherein said vesicles of said first dispersion are formed of at least one lipid mixture selected from the group consisting of:
triglyceryl cetyl ether, cholesterol, and casein lipoamino acid; mixtures of triglyceryl mono-, di- and tricetyl ether, cholesterol, and dicetyl phosphate; triglyceryl cetyl ether, cholesterol, and dicetyl phosphate; sorbitan palmitate, cholesterol, and sodium acylglutamate; PEG 8 stearate, cholesterol, and sodium acylglutamate; diglyceryl distearate, cholesterol, and sodium acylglutamate; sucrose mono- and distearate, cholesterol, and sodium acylglutamate; PEG 8 stearate, cholesterol, phytanetriol, and sodium acylglutamate; polyoxyethylenated methylglucose distearate containing 20 mol of ethylene oxide, cholesterol, and sodium acylglutamate; hydrogenated lecithin, and polyoxyethylenated phytosterol; and tetraglyceryl tristearate, cholesterol, and sodium acylglutamate.
7. The composition of claim 1, wherein said vesicles of said second dispersion are formed of lipids selected from the group consisting of natural ionic phospholipids having unsaturated fatty chains having from 16 to 30 carbon atoms, polyol alkyl ethers or polyol alkyl esters having one or more fatty chains per molecule, including at least one fatty chain with a length of less than 16 carbon atoms, and mixtures thereof.
8. The composition of claim 1 wherein said vesicles of said second dispersion are formed of at least one lipid or lipid mixture selected from the group consisting of sunflower lecithin;
soya lecithin, ethanol, and water; soya lecithin, cholesterol, and propylene glycol; and lauryl polyglyceryl-6-cetearyl glycol ether and dimyristyl phosphate.
9. The composition of claim 1, wherein said active agent of said first dispersion and said active agent of said second dispersion provide the same function, the same effect, or both.
10. The composition of claim 1, wherein said active agent of said first dispersion and said active agent of said second dispersion are the same.
11. The composition of claim 1, wherein said active agent contained in said first dispersion is selected from the group consisting of retinol and retinol compounds; tretinoin and isotratinoin; octopirox; triclosan; hexamidine and salts thereof; chlorhexidine and salts thereof; azelaic acid and salts thereof; zinc salts and zinc oxide; clindamycin; N,N-dimethyl-N-2-(hydroxyethyl)ammonium 5-n-dodecanoylsalicylate; ketoconazole; hydrocortisone and hydrocortisone compounds; acetylsalicylic acid; and β-glycyrrhetinic acid.
12. The composition of claim 1, wherein said active agent contained in said second dispersion is selected from the group consisting of 5-n-octanoylsalicylic acid, salicylic acid, anti-squalene-peroxidation active agents; nitroxide radicals; sunscreen agents; α-hydroxy acids; and polyols.
13. The composition of claim 1, further comprising
(c) an oily phase dispersed in an aqueous phase.
14. The composition of claim 1, further comprising
(d) a hydrophilic or lipophilic adjuvant.
15. A method for treating acne, comprising applying to the skin of a subject in need thereof an effective amount of a composition comprising a dispersion mixture of:
(a) a first dispersion of lipid vesicles which are capable of penetrating into the deep layers of the skin and containing at least one active agent selected from the group consisting of antimicrobial agents, anti-inflammatory agents, anti-seborrhoeic agents, retinol and retinol compounds, for treating these deep layers; and
(b) a second dispersion of lipid vesicles which are capable of penetrating into the layers of the stratum corneum of the skin and which contain at least one active agent selected from the group consisting of keratolytic agents, protective agents, moisturizing agents and anti-oxidants, for treating these layers of the stratum corneum,
and wherein said vesicles of said first dispersion ensure a distribution of N-(1-oxyl-2,2,6,6-tetramethyl-4-piperidyl)-N-dimethyl-N-hydroxyethylammonium iodide (ASL) in the stratum corneum>1 that said vesicles of said second dispersion ensure a distribution of ASL in the stratum corneum<1
Description
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The Applicant has used a means of classifying vesicles which enables a person skilled in the art readily to select lipid vesicles capable of conveying the active agent to the deep layers of the skin, known as vesicles with deep-down action, and those capable of conveying the active agent to the surface layers of the skin, known as vesicles acting at the surface.

This classification is made on the basis of the diffusion constant D of a probe introduced into the vesicles. This probe is N-(1-oxyl-2,2,6,6-tetramethyl-4-piperidyl)-N,N-dimethyl-N-hydroxyethylammonium iodide (ASL), of formula (I): ##STR1##

Vesicles for which the diffusion constant D of the probe into the stratum corneum is >1 capable of penetrating into the deep layers of the skin.

Vesicles for which the diffusion constant D of the probe into the stratum corneum is <1 capable of conveying the active agent to the surface layers of the skin.

The vesicles of the first type, the so-called vesicles with deep-down action, are generally in the fluid state at room temperature (about 20 acting at the surface, are generally in the gelled state at room temperature. The means of recognizing the state of the vesicles consists in determining the phase (fluid-gel lamellar) transition temperature of the main lipid constituting the membrane thereof, by differential thermal analysis (DTA).

Other characteristics of these vesicles relate to their ability to deliver the active agent to a greater or lesser depth in the skin. This is particularly the case for the degree of encapsulation.

Glucose is a labelling agent conventionally used for this type of determination (see in particular Liposomes a practical approach by R. R. C. New, IRL Press, pp. 125-136 (1990)).

The degree of encapsulation is expressed as the volume of glucose solution encapsulated in the vesicles, measured in μl relative to the unit weight (mg) of the lipids constituting the membrane. This degree of encapsulation is determined immediately after the step of separation of the free glucose and of the encapsulated glucose (T.sub.o), an well as twenty-four hours after this separation (T.sub.24 hours).

The difference between these two successive determination illustrates the permeability of the vesicles with respect to the encapsulated glucose, which may also be referred to as their encapsulation potential.

The first type of vesicles (delivering the active agent into the deep layers of the skin) has a high encapsulation potential for the small water-soluble molecules which are conventionally modelled by glucose, this encapsulation potential being maintained for at least 24 hours. The second type of vesicles (delivering the active agent into the surface layers of the skin) does not retain glucose in the encapsulated state for the same amount of time.

The main lipids constituting the vesicles of the first type (deep delivery of the active agent) are composed of at least one linear and saturated fatty chain of length ranging from 16 to 30 carbon atoms, such an hydrogenated phospholipids (from plants or from eggs), saturated synthetic phospholipids such as dipalmitoylphosphatidylcholine, and polyol alkyl ethers or polyol alkyl eaters containing one, two or three fatty chains per molecule. These lipide are used alone or as a mixture.

The main lipids constituting the vesicles of the second type (active agent delivered at the surface) are chosen in particular from the group comprising ionic lipids, especially such as natural plant- or egg-based phospholipids, containing unsaturated fatty chains having from 16 to 30 carbon atoms; nonionic lipids such an polyol alkyl ethers or polyol alkyl esters containing one or more fatty chains per molecule, including at least one fatty chain with a length of less than 16 carbon atoms, such as lauryl polyglyceryl-6-cetearyl glycol ether, described in detail in French Patent Application FR 92-09603 filed by L'Oreal.

It is possible, in a known manner, to incorporate into the lipid phase constituting the lipid membrane of the vesicles, at least one additive chosen from the group formed of sterols (phytosterols, cholesterol or polyoxyethylenated phytosterols); long-chain alcohols, diols and triols (phytanetriol), long-chain amines and the quaternary ammonium derivatives thereof; phosphoric esters of fatty alcohols and the alkali metal (Na or K) salts thereof, such an dicetyl phosphate, sodium dicetyl phosphate, alkyl sulfates (sodium cetyl sulfate), alkali metal salts of cholesterol sulfate or of cholesterol phosphate, the sodium salt of phosphatidic acid, and lipoamino acids and the salts thereof, such as the sodium acylglutamates.

Examples of vesicles of the first category (delivering the active agent into the deep layers of the skin) which may be mentioned are vesicles obtained from the following lipids (CTFA name):

A/cholesterol/casein lipoamino acid, especially in a 45/45/10 weight ratio (where A is a triglyceryl cetyl ether marketed by the company Chimex under the name Chimexane NL);

B/cholesterol/dicetyl phosphate, especially in a 60/35/5 weight ratio (where B is a mixture of triglyceryl mono-, di- and tricetyl ether, marketed by the company Chimex under the name Chimexane NT);

Span 40 (from ICI, or Sorbitan palmitate)/cholesterol/sodium acylglutamate (marketed under the same HS11 by the company Ajinomoto), especially in a 47.5/47.5/5 weight ratio;

PEG 8 stearate/cholesterol/sodium acylglutamate, especially with a 47.5/47.5/5 weight ratio (where PEG 8 stearate is polyethylene glycol containing 8 units of ethylene oxide, marketed by the company Unichema under the name PEG 400 stearate);

PEG 8 stearate/cholesterol/phytanetriol/sodium acylglutamate, especially with a 47.5/20/27.5/5 weight ratio;

Hydrogenated lecithin/polyoxyethylenated phytosterol containing 5 units of ethylene oxide, especially in a 60/40 weight ratio;

Polyoxyethylenated methylglucose distearate containing 20 units of ethylene oxide/cholesterol/sodium acylglutamate, especially in a 45/45/10 weight ratio (the distearate being, for example, that sold under the name Glucam E 20 distearate by Amerchol);

A/cholesterol/dicetyl phosphate, especially with a 47.5/47.5/5 weight ratio;

Diglyceryl distearate (for example that sold by Nihon under the name Emalex DS G2)/cholesterol/sodium acylglutamate, in a 45/45/10 weight ratio;

Sucrose mono- and distearate (for example that sold by Grillo under the Grilloten PSE 141 G)/cholesterol/sodium acylglutamate, especially in a 45/45/10 weight ratio;

Tetraglyceryl tristearate (for example that sold by Nikkol under the name Tetraglyn 3S)/cholesterol/sodium acylglutamate, especially in a 45/45/10 weight ratio.

Examples of vesicles of the second type (delivering the active agent into the surface layers of the skin) which may be mentioned are vesicles obtained from the following lipids:

Sunflower lecithin;

Natipide II (soya lecithin/ethanol/water in a 20/16/64 weight ratio, marketed by Nattermann);

C (soya lecithin/cholesterol/propylene glycol in a 60/20/20 weight ratio, marketed by Nattermann under the name NAT 50 PG);

D/dimyristyl phosphate, especially in a 95/5 weight ratio (where D is a lauryl polyglyceryl-6-cetearyl glycol ether marketed by the company Chimex under the name Chimexane NS).

Table I below gives, for some of the vesicles obtained using the above lipids, the diffusion constant D for ASL in the stratum corneum and in the epidermis/dermis, as well as the degree of encapsulation of glucose and the phase transition temperature of the main lipid constituting the membrane. The diffusion constant was measured for an encapsulated ASL concentration of 0.35% by weight relative to the total weight of the composition.

                                  TABLE I__________________________________________________________________________                 Diffusion                 coefficient                           Degree of                 D in 10.sup.-7 cm.sup.2 s.sup.-1                           encapsulation                                  Phase         Proportions                 in the                      in the                           of glucose in                                  transition         % by weight                 stratum                      epidermis/                           μl/mg                                  temperatureRef.   LIPID SYSTEMS         (mg)    corneum                      dermis                           T.sub.o                              T.sub.24h                                  in __________________________________________________________________________   1st type - deep down1  A/cholesterol/casein         45/45/10                 42   5    7.5                              6.8 50   lipoamino acid         (67.5/67.5/15)2  B/cholesterol/dicetyl         60/35/5 58   2    11.1                              11.1                                  54   phosphate  (90/52.5/7.5)3  Span 40/cholesterol/         47.5/47.5/5                 42   2    13.8                              13.8                                  50   sodium acylglutamate         (71.25/71.25/7.5)4  PEG 8 stearate/         47.5/47.5/5                 42   2    14.4                              14.4                                  55   cholesterol/sodium         (71.25/71.25/7.5)   acylglutamate5  PEG 8 stearate/         47.5/20/27.5/5                 8.3  2.5  4.1                              3.0 55   cholesterol/phytanetriol/         (71.25/30/   sodium acylglutamate         41.25/7.5)6  Hydrogenated lecithin/         60/40   8    2    6.0                              4.8 80   polyoxyethylenated         (90/60)   phytosterol   2nd type - surface7  Sunflower lecithin         100     0.3  0.2  1.6                              0   <0         (150)8  Natipide II (soya         20/16/64                 0.4  0.2  0.4                              0   <0   lecithin/ethanol/water)         (30/24/96)9  C (soya lecithin/         60/20/20                 0.25 0.1  1.8                              0   <0   sterols/propylene glycol)         (90/30/30)10 D/dimyristyl phosphate         95/5    0.3  0.2  2.0                              0   14         (142.5/7.5)__________________________________________________________________________

Measurement of the diffusion constant D is carried out by combining two methods using a paramagnetic probe, ASL: one-dimensional and periodic electron paramagnetic resonance (EPR), on the one hand, and EPR kinetic imaging, on the other hand. These two methods are respectively described in the articles "Evaluation of liposomes as drug carriers into the skin by one-dimensional EPR imaging" by V. Gabrijelcic et al., International Journal of Pharmaceutics, vol. 62, pp. 75-79, Elsevier (1990), and "Liposome entrapped molecules penetration into the skin measured by nitroxide reduction kinetic imaging" by V. Gabrijelcic et al., Periodicum Biologorum, vol. 93, No. 2, pp. 245-246 (1991).

Measurement of the degree of encapsulation is carried out as described in Liposomes a practical approach by R. R. C. New, IRL Press, pp. 125-136 (1990) cited previously, and that of the phase transition temperature is carried out as described above.

Advantageously, several active agents are used simultaneously in each type of vesicles, these active agents having the same function and/or imparting to the skin, at the surface and deep down, the same type of effect; the agents active at the surface and the agents with deep-down action are thus complementary.

The active agents with deep-down action and the agents active at the surface which may be used in the present invention are those which are conventionally used in the cosmetic or dermatological field.

The active agents with deep-down action are in particular chosen from retinol (vitamin A) and the derivatives thereof, such as retinol acetate, propionate or palmitate; tretinoin and isotretinoin.

Antiseptic agents which may be mentioned are triclosan; hexamidine and the salts thereof, such as hexamidine diisothionate; chlorhexidine and the salts thereof, such an chlorhexidine diacetate or digluconate; azelaic acid and the salts thereof, such an the acetate.

Anti-seborrhoeic agents which may be mentioned are octopirox, and zinc salts such as zinc cysteate, and zinc oxide.

Antimicrobial agents which may be mentioned are clindamycin and other antibiotics of erythromycin type; N,N-dimethyl-N-(2-hydroxyethyl)ammonium 5-n-dodecanoylsalicylate, abbreviated to DHADS; katoconazole and other antifungal agents such an clotrimozol.

As non-steroidal anti-inflammatory active agents which may be used in the invention, there may be mentioned ASPIRIN OXYCAMS

As steroidal anti-inflammatory active agents which may be used in the invention, there may be mentioned hydrocortisone and the derivatives thereof, such an hydrocortisone acetate, phosphate or butyl acetate.

The agents active at the surface are advantageously chosen from keratolytic agents, for instance 5-n-octanoylsalicylic acid, salicylic acid, α-hydroxy acids such an lactic acid, glycolic acid or tartaric acid, or from fruit; antioxidants, for instance nitroxide radicals, anti-squalene-peroxidation active agents such as tocopherol and the derivatives thereof, sequestering agents and glucosyl quercetin; protective agents, for instance sunscreen agents; moisturizing agents, for instance polyols such as glycerine.

Screening agents which may be mentioned as a guide are: p-aminobenzoic acid and the derivatives thereof (glyceryl, ethyl and isobutyl esters); anthranilates (such as the o-aminobenzoate or the alkyl esters); salicylates; cinnamic acid derivatives; dihydroxycinnamic acid derivatives; trihydroxycinnamic acid derivatives; hydrocarbons (stilbene); dibenzalacetone and benzalacatophenone; coumarin derivatives; hydroxy- or methoxy-substituted benzophenones; tannic acid and the derivatives thereof; benzophonones and any other sunscreen agent conventionally used in the cosmetic and/or dermatological field, such as benzylidenecamphor, benzene-1,4-di(3-methylidene-10-camphorsulfonic) acid or alternatively 4-(3-methylidenecamphor)phenyltrimethylammoniummethyl sulfate, as well as mixtures thereof, 2-ethylhexyl 2-cyano-3,3'-diphanylacrylate or alternatively dibenzoylinethane.

Pigments or nanopigments may also be used, especially those of zinc oxide and/or of titanium oxide (TiO.sub.2, ZnO.sub.2).

As nitroxide radicals which may be used in the invention, there may be mentioned 2,2,6,6-tetramethylpiperidine 1-oxide, 4-hydroxytetramethylpiperidine 1-oxide, docylcyclohexane and N-tert-butyl-alpha-phenylnitrone.

The agents active at the surface and the agents with deep-down action may be present in an amount from 0.02 to 10% by weight, preferably 0.1 to 5% by weight, based on the total weight of the composition.

The compositions according to the present invention may be provided in all the pharmaceutical forms normally used for topical application, such as aqueous gels, emulsions, lotions, ointments, sera and, more particularly, vesicle-dispersed oil droplets such as those described in French patents FR-A-2,485,921 and FR-A-2,490,504.

As is known, in addition to the vesicles, a vegetable oil, mineral oil, silicone-containing oil or synthetic oil which is dispersed in an aqueous phase, and also hydrophilic adjuvants such an gelling agents, antioxidants, preserving agents, opacifying agents, lipophilic adjuvants such as essential oils and fragrances, pigments and fillers, may be found in the compositions of the present invention, as described in the above French patents. For example, polyethylene beads may be added to provide a cleaning action (scrub). The dispersed oil may be present in an amount of from 2 to 40% by weight, preferably 5 to 20% by weight, based on the total weight of the composition, and the adjuvants may be present in a total amount of from 0.1 to 10% by weight, preferably 1 to 5% by weight, based on the total weight of the composition.

The invention also relates to a use of the composition defined above for the preparation of an ointment intended to treat acne and to a process for treating acne, by in applying this composition to the skin.

The vesicles of both the first and second types suitably comprise 1 to 90% by weight, preferably 5 to 70% by weight, more preferably 5 to 20% by weight, of the total weight of the composition.

The relative amounts of the vesicles of the first and second types in the present compositions are suitably:

10 to 90% by weight of the vesicles of the first type, and

90 to 10% by weight of the vesicles of the second type, preferably:

30 to 70% by weight of the vesicles of the first type, and

70 to 30% by weight of the vesicles of the second type,

based on the total weight of the vesicles of the first and second types.

Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

EXAMPLES

In all of the Examples, the term "qs 100 g" means that that ingredient is added in a amount sufficient to make the total amount of all ingredients equal 100 g.

A. production of lipid vesicles containing ASL:

The constituent lipids of the wall of the vesicles are weighed and dissolved in 10 ml of methanol. The alcoholic solution is then transferred into a 50 ml round-bottomed flask with a ground joint, which in subsequently placed on a rotary evaporator such that the contents are thermostatted at a temperature of 30 continued until a dry film of lipids is deposited on the wall of the flank.

3 ml of an aqueous 0.01 molar solution of ASL are then added to the flask, which is subsequently shaken by hand for about 10 minutes, either at room temperature (20 7 to 10, or at a temperature of 50 reference Nos. 1 to 6 of Table I. The medium is then left to equilibrate at room temperature for 2 hours, after which the dispersion is placed in a dialysis bag and in contact with 500 ml of distilled water. Dialysis taken place overnight. The next day, the water in changed and the dialysis is continued for a further 4 hours.

A cotton thread 0.3 mm thick is then soaked in the vesicle dispersion and then placed in contact with a section of skin cut from a pig's ear which has been freshly taken from an abattoir intended for food supply.

The ear sample taken is rinsed with water and cut into slices 1 mm thick, 5 mm wide and 10 mm long and then placed in a maintenance cell. Measurements of the diffusion of ASL into the skin are made in the 24 hours following the taking of the skin sample.

B. Production of the cosmetic composition:

1. Production of vesicles of the first type (diffusing deep down).

The vesicles (with deep-down action) are prepared according to a common method for co-fusion of the various membranes constituents chosen (see Table I). Thus, the membrane constituent having the lowest melting point T.sub.m is melted. The other membrane constituents are added thereto and the mixture is then homogenized with moderate stirring and is finally partially hydrated, while maintaining the melting temperature T.sub.m defined above.

An aqueous solution of at least a first active agent for the deep-down treatment is added to the paste obtained. The mixture is stirred with a turbine for 1 hour and 30 minutes in order to hydrate fully, while maintaining the temperature T.sub.m. One or more other active agents for the deep-down treatment are added to the reaction medium, homogenization is carried out and the temperature of the medium is lowered to room temperature (20

2. Production of vesicles of the second type diffusing at the surface).

An aqueous solution of one (or more) second active agent for the surface treatment is introduced, at room temperature (20 simple stirring, into the chosen mixture of constituents which are to form the membrane of the vesicles acting at the surface (see Table I). Vesicles acting at the surface encapsulating the second active agent acting at the surface are thus obtained.

3. Production of the "double-liposome" composition.

The fatty phase (the oils) of the composition is added to the medium containing the vesicles with deep-down action, and it is dispersed (at room temperature) with stirring. The reaction medium obtained is then mixed with that containing the vesicles acting at the surface. The adjuvants, such as preserving agents, a gelling agent which may be neutralized if necessary with a base (triethanolamine or sodium hydroxide), and fragrances, etc., are then optionally added.

The product obtained is in the form of a soft and smooth white cream which may be used in the cosmetic and/or dermatological field for the treatment of acne on the face and/or body.

The invention also relates to the use of the composition defined above and to a process for treating acne, consisting in applying a composition as defined above to the human face and/or body. The invention also relates to the use of this composition for the preparation of a dermatological ointment intended for the treatment of acne.

Specific examples of cosmetic compositions in accordance with the invention are given below.

Example 1: Anti-acne Double-liposome Cream

______________________________________Preparation A: Liposomes with deep-down action:Triglyceryl cetyl ether          8.1 gCholesterol                      8.1 gDHADS (active agent)             1.8 gMethylparaben (preserving agent) 0.1 gGlycerine                        12.0 gDemineralized water       qs     100 gPreparation B: Liposomes acting at the surface:Chimexane NS/dimyristyl phosphate                            20.0 gin a 95/5 weight ratioSalicylic acid (active agent)    2.0 gGlycerine                        15.0 gMethylparaben (preserving agent) 0.2 gDemineralized water       qs     100 gDouble-liposome composition:Preparation A                    33.3 gPreparation B                    25.0 gVegetable oil                    3.0 gVolatile silicone oil            4.5 gTriclosan (active agent)         0.2 gPreserving agents                0.3 gCarboxyvinyl polymer (gelling agent)                            0.9 gSodium hydroxide                 1.8 gDemineralized water       qs     100 g______________________________________

The cream obtained may be applied daily in order to attenuate, or even to eradicate, comedones caused by acne.

Example 2: Anti-acne Double-liposome Cream

This cream differs from that of Example 1 in that 5-n-octanoylsalicylic acid is used as the agent acting at the surface, in place of salicylic acid.

Example 3: Anti-acne Double-liposome Cream

______________________________________Preparation A: Liposomes with deep-down action:Triglyceryl cetyl ether          7.6 gCholesterol                      7.6 gSodium acylglutamate             0.8 gTretinoin (active agent)         0.2 gMethylparaben (preserving agent) 0.1 gGlycerine (active agent)         15.0 gDemineralized water       qs     100 gPreparation B: Liposomes acting at the surface:Chimexane NS                     20.0 gGlycerine (active agent)         15.0 gGlycolic acid (active agent)     3.0 gMethylparaban (preserving agent) 0.2 gDemineralized water       qs     100 gDouble-liposome composition:Preparation A                    25.0 gPreparation B                    25.0 gHydrogenated isoparaffin         3.0 gCarboxyvinyl polymer (gelling agent)                            0.9 gSodium hydroxide                 1.8 gPreserving agents                0.6 gAntioxidants                     0.2 gDemineralized water       qs     100 g______________________________________

This application is based on French Patent Application 93-15865 filed on Dec. 30, 1993, which is incorporated herein by reference in its entirety.

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to compositions for the cosmetic or dermatological treatment of imperfections or complaints of the skin, including the scalp. It relates more particularly to an anti-acne composition, comprising at least one active agent which is conveyed via at least two distinct types of lipid vesicles. The present invention also relates to a method for the anti-acne treatment of the skin.

2. Discussion of the Background

Acne is one of the diseases usually affecting, and to varying degrees, the juvenile population between the ages of 15 and 30. Ache is due essentially to the increased production, at puberty, of androgens such an testosterone, which stimulate the sebaceous glands in order to raise the production of sebum. Hyperkeratinization of the follicular duct is observed simultaneously, creating in the pilosebaceous follicle an environment which in rich in nutrients for the bacterial flora and which especially promotes the proliferation of diphtheroid anaerobic germs such as the Propionibacteria (acnes, granulosnm, avidum) and, consequently, inflammation of the skin.

Acne treatments which are generally used are keratolytic agents such as salicylic acid or the derivatives thereof, for the purpose of removing dead or hyperkeratinized skin, and antibacterial agents.

Many examples are known of cosmetic or dermatological compositions intended for treating the skin, which have one or more active agents that are suitable for treating the skin and which are encapsulated in lipid spherules or vesicles (also known an liposomes).

Lipid spherules or vesicles are understood to refer to particles formed of a membrane consisting of one or more concentric lamellae, these lamellae containing one or more bimolecular layers of amphiphilic lipids encapsulating an aqueous phase. The aqueous phase may contain water-soluble active substances and the bimolecular layers of amphiphilic lipids may contain lipophilic active substances.

These spherules generally have a mean diameter of between 10 nm and 5000 nm.

Among the many documents published regarding this matter, there may be mentioned the French Certificate of Addition 2,408,387 which describes a composition based on aqueous dispersions of ionic or nonionic lipid spherules encapsulating at least one active substance. More precisely, this document describes compositions containing at least two dispersions of spherules containing different active agents, for the purpose of obtaining a mixed system, that is to say a system in which a first dispersion of spherules containing a first type of active substance in combined with a second dispersion of spherules containing another type of active substance, which enables the two types of substances to act simultaneously at the time of treatment and possibly to obtain a synergistic effect which would not be produced if these two types of substances were made to act successively and separately.

Skin disorders of the acne type concern both an attack on the surface layers of the skin and a related impairment of the deeper layers of the epidermis and of the dermis.

It is well known that the skin consists of surface layers, the stratum corneum, and of deep layers, the live epidermis and the dermis. However, specific delivery of such an active agent into the surface layers and, simultaneously, of the same or another active agent into the deep layers, is not known from the prior art.

Thus, there remains a need for treating acne which treats both the stratum corneum and the deep layers of the skin. There also remains a need for compositions useful in such methods.

SUMMARY OF THE INVENTION

Accordingly, it is one object of the present invention to provide a novel method for the treatment of acne.

It is another object of the present invention to provide a method for treating acne which simultaneously treats the surface layers and deep layers of the skin.

It is another object of the present invention to provide novel compositions useful in such methods.

These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compositions which comprise

(a) first dispersion of lipid vesicles which are capable of penetrating into the deep layers of the skin and which contain at least one active agent chosen from antimicrobial agents, antiseptic agents, anti-inflammatory agents, anti-seborrhoeic agents, antibiotics, retinol (vitamin A) and the derivatives thereof, for treating these deep layers; and

(b) a second dispersion of lipid vesicles which are capable of penetrating into the surface layers of the skin and which contain at least one active agent chosen from keratolytic agents, protective agents, moisturizing agents and antioxidants, for treating these surface layers, are effective for the simultaneous anti-acne treatment of the surface layers of deep layers of the skin.

The inventors have now developed cosmetic and/or dermatological anti-acne compositions, which allow the simultaneous action of two different active agents, and which furthermore allow these active agents to act in different areas of the skin, that is to say in the surface layers and in the deep layers of the skin, thereby very markedly enhancing the effectiveness of these compositions and the complementary or synergistic effect of the anti-acne active agents used.

The inventors have also developed cosmetic or dermatological anti-acne compositions, which enable the same active agent to act simultaneously in the surface layers and in the deep layers of the skin, providing a more complete and therefore a more effective treatment of the disorder from which it is suffering.

According to a specific embodiment, the active agents contained in the first dispersion of vesicles and in the second are the same.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US4217344 *29 déc. 197712 août 1980L'orealCompositions containing aqueous dispersions of lipid spheres
EP0571063A1 *16 août 199324 nov. 1993Schering AktiengesellschaftPharmaceutical preparations
Citations hors brevets
Référence
1Lasch et al. "How deep do intact liposomes penetrate into human skin?", J. q controlled release 18, #1, Jan. 1992 pp. 55-58.
2 *Lasch et al. How deep do intact liposomes penetrate into human skin , J. q controlled release 18, 1, Jan. 1992 pp. 55 58.
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US5866148 *23 juin 19972 févr. 1999Societe L'oreal S.A.Photoprotective compositions comprising mutually incompatible oily dispersed phases
US5985925 *9 sept. 199816 nov. 1999Societe L'oreal S.A.Photoprotective/cosmetic compositions comprising UV-sunscreens/dialkyl tartrates
US6022896 *10 sept. 19988 févr. 2000Chesebrough-Pond's Usa Co.Petroselinic acid as an anti-irritant in compositions containing alpha-hydroxy acids
US6042841 *15 mars 199928 mars 2000Unilever Home & Personal Care Usa Division Of Conopco, Inc.Cosmetic method of treating skin
US618377417 août 19996 févr. 2001Collaborative Laboratories, Inc.Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US64446477 avr. 20003 sept. 2002The Procter & Gamble CompanySkin care compositions containing combination of skin care actives
US65212373 juin 199918 févr. 2003Johnson & Johnson Consumer Companies, Inc.Skin care composition
US65445319 nov. 19998 avr. 2003Johnson & Johnson Products, Inc.Skin care composition
US67736274 déc. 200310 août 2004Children's Hospital Research FoundationCubic liquid crystalline compositions and methods for their preparation
US681822624 juil. 200116 nov. 2004Acrux Dds Pty. Ltd.Dermal penetration enhancers and drug delivery systems involving same
US686106021 avr. 20001 mars 2005Elena LuriyaPersonal care formulations
US7078048 *9 mai 200218 juil. 2006The Regents Of The University Of MichiganMethod and compositions for treating rosacea
US709442220 août 200322 août 2006Acrux Dds Pty Ltd.Topical delivery of antifungal agents
US7252816 *29 mars 20067 août 2007Dow Pharmaceutical SciencesTopical acne vulgairs medication with a sunscreen
US7285544 *18 nov. 200423 oct. 2007Bernstein Eric FUse of nitroxides in treating skin disease
US728557017 avr. 200323 oct. 2007The Procter & Gamble CompanyCompositions and methods for regulating mammalian keratinous tissue
US7326408 *27 juin 20075 févr. 2008Dow Pharmaceutical SciencesTopical acne vulgaris medication with a sunscreen
US73877898 sept. 200617 juin 2008Acrux Dds Pty. Ltd.Transdermal delivery of non-steroidal anti-inflammatory drugs
US73965265 mai 20008 juil. 2008Johnson & Johnson Consumer Companies, Inc.Skin care composition
US741675610 sept. 200326 août 2008Eastman Chemical CompanyProcess for the recovery of a phytolipid composition
US743820320 janv. 200421 oct. 2008Acrux Dds Pty LtdDermal penetration enhancers and drug delivery systems involving same
US749141212 mai 200417 févr. 2009Eastman Chemical CompanyProcess for the recovery of a phytolipid composition
US779530230 nov. 200514 sept. 2010The Regents Of The University Of MichiganUse of compositions for treating rosacea
US801681023 juin 200413 sept. 2011Transpharma Medical Ltd.Transdermal delivery system for cosmetic agents
US80530005 juin 20068 nov. 2011Dr. Reddy's Laboratories LimitedCompositions for drug delivery
US806309714 août 200722 nov. 2011The Procter & Gamble CompanyCompositions and methods for regulating mammalian keratinous tissue
US80710755 oct. 20076 déc. 2011Acrux Dds Pty Ltd.Dermal penetration enhancers and drug delivery systems involving the same
US831878614 août 200827 nov. 2012The University Of ChicagoPlant pathogen resistance
US860353917 oct. 201110 déc. 2013Dr. Reddy's Laboratories LimitedCompositions for drug delivery
US861757812 mars 201231 déc. 2013L'orealCompositions containing topical-active agents and pentyleneglycol
US20120156147 *29 juin 201021 juin 2012Natura Cosmeticos S.A.Cosmetic composition; skin treatment kit; method for treating oily or mixed skin or acned skin
CN102366407B14 sept. 201120 mars 2013海南灵康制药有限公司Clindamycin palmitate hydrochloride liposome solid preparation
DE10251709A1 *6 nov. 200212 févr. 2004ColeticaWirkstoffe zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3 und kosmetische oder pharmazeutische Zusammensetzungen, die solche Wirkstoffe enthalten
DE10251709B4 *6 nov. 200227 nov. 2008Engelhard Lyon S.A.Screening-Verfahren für Wirkstoffe zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3
DE10251709C5 *6 nov. 200224 févr. 2011Engelhard Lyon S.A.Screening-Verfahren für Wirkstoffe zur Stimulierung der humanen beta-Defensine vom Typ 2 und/oder Typ 3
EP1358876A1 *30 avr. 20025 nov. 2003Cognis Iberia, S.L.Microcapsules containing anti-acne agents
EP1596876A1 *12 févr. 200423 nov. 2005Euro-Celtique S.A.Use of pvp-iodine liposomes for treatment of acne
WO1999022703A1 *18 oct. 199814 mai 1999Lurident LtdImproved personal care formulations
WO2001085129A2 *4 mai 200115 nov. 2001Johnson & Johnson ConsumerSkin care composition
WO2003092664A1 *22 avr. 200313 nov. 2003Carmen AriasMicro-capsules with anti-acne active ingredients
WO2006133131A1 *6 juin 200614 déc. 2006Vakati Venkat ArvindCompositions for drug delivery
WO2007126915A1 *28 mars 20078 nov. 2007Dow Pharmaceutical SciencesTopical acne vulgaris medication with a sunscreen
Classifications
Classification aux États-Unis424/450, 424/401, 514/859, 514/846
Classification internationaleA61K8/63, A61K8/00, A61K8/41, A61K8/86, A61K9/127, A61K8/14, A61K8/27, A61K8/30, A61K8/36, A61K8/44, A61K8/19, A61K8/49, A61K8/368, A61Q17/00, A61K9/133, A61K8/39, A61K8/34, A61P17/12, A61P31/04, A61K8/04, A61P17/18, A61K8/92, A61K8/60, A61Q19/00, A61K31/575, A61P29/00, A61K8/37, A61K45/00, A61K8/85, A61K8/67
Classification coopérativeY10S514/859, Y10S514/846, A61K8/368, A61K8/14, A61K9/127, A61K8/671, A61Q19/00, A61K8/347
Classification européenneA61Q19/00, A61K8/67C, A61K8/14, A61K8/368, A61K9/127, A61K8/34F
Événements juridiques
DateCodeÉvénementDescription
25 mars 2009FPAYFee payment
Year of fee payment: 12
23 mars 2005FPAYFee payment
Year of fee payment: 8
29 mars 2001FPAYFee payment
Year of fee payment: 4
16 mai 1995ASAssignment
Owner name: L OREAL, FRANCE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FANCHON, CHANTAL;RIBIER, ALAIN;SIMONNET, JEAN-THIERRY;AND OTHERS;REEL/FRAME:007478/0381;SIGNING DATES FROM 19950321 TO 19950404